Premier Path Wealth Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Premier Path Wealth Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$473K	Sell	16,265 -2,000	-11%	-$53K	0.06%	268
2026 Q2	$328K	Sell	18,265 -2,000	-10%	-$30.9K	0.04%	346
2026 Q1	$282K	Hold	20,265	–	–	0.04%	354
2025 Q4	$245K	Hold	20,265	–	–	0.03%	361
2025 Q3	$275K	Hold	20,265	–	–	0.04%	345
2025 Q2	$130K	Hold	20,265	–	–	0.02%	384
2025 Q1	$71.7K	Buy	+20,265	New	+$72.1K	0.01%	372
2024 Q4	–	Sell	-20,265	Closed	-$65.7K	–	370
2024 Q3	$65.7K	Buy	+20,265	New	+$45.6K	0.01%	364
2024 Q2	–	Sell	-20,265	Closed	-$57.6K	–	369
2024 Q1	$57.6K	Hold	20,265	–	–	0.01%	343
2023 Q4	$298K	Buy	+20,265	New	+$311K	0.07%	261

Other funds holding AMLX

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

V-Square Quantitative Management Chicago, Illinois $1.09B AUM 23.97% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CAIM

Catherine Avery Investment Management Longboat Key, Florida $116M AUM 31.75% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Premier Path Wealth Partners's AMLX Position: Q3 2026 in Review

Premier Path Wealth Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 11% in Q3 2026, selling an estimated $53K and leaving 16,265 shares worth $473K. The position accounts for 0.06% of the portfolio, ranked #268.

Premier Path Wealth Partners first reported a position in AMLX in Q4 2023 and has held it in 10 quarters since. 12 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Premier Path Wealth Partners held 16,265 shares of Amylyx Pharmaceuticals worth $473K as of Q3 2026.
Premier Path Wealth Partners sold 2,000 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $53K.
Amylyx Pharmaceuticals made up 0.06% of Premier Path Wealth Partners's portfolio in Q3 2026, its #268 holding.
Premier Path Wealth Partners first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
12 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Premier Path Wealth Partners's 13F filing for Q3 2026, filed 16 Oct 2026.